Our technology
Innovative purification platforms built for industrial reality
Askleia’s technology addresses the key economic and operational challenges associated with the purification of biomedicines. Our technology is designed to improve resolution and efficiency and to be adaptable, transferable and scalable.
Y Serie
Precipitation on continuous flow
Current protein A capture chromatography technology, whilst effective, relies on the use of an expensive gel that generates waste. These chromatography columns require a significant investment, which increases both production costs and the environmental footprint. Our ‘Y-Series’ technology offers an innovative alternative: continuous process based, requiring no solid phase and no regeneration, which is more environmentally friendly.
By eliminating this step, we significantly reduce waste whilst simplifying the purification process. The result: substantial savings, a reduced environmental impact and more sustainable production. “Y-Series” stands out as a breakthrough solution, designed to meet the industrial demands of today and tomorrow.
F Serie
Continuous Free-flow Electrophoresis
Traditional ion-exchange (anionic and cationic) and steric exclusion chromatography techniques have limitations: they require expensive solid phases, generate substantial waste and sometimes offer insufficient selectivity, particularly for molecules of similar size or charge.
Our ‘F-Series’, microfluidics technology offers an innovative alternative that replaces both these methods with a single one, without the need for a solid phase, based on the principle of electrophoresis in continuous flow. This approach significantly reduces waste, lowers production costs and minimises the environmental footprint. Furthermore, it offers enhanced separation power, enabling more precise and efficient purification of biopharmaceuticals.
By adopting the “F-Series”, you are choosing a sustainable, cost-effective and high-performance solution, tailored to the current demands of the biopharmaceutical industry.
Technology Objective
Technology profile based on microfluidique in continuous flow
Aaskleia's approach is rooted in a deep understanding of the physicochemical properties governing biomolecule behaviour during separation.
From first principles
Rather than adapting existing purification hardware to new molecules, our technologies are engineered from first principles — targeting the specific binding, selectivity, and elution mechanisms that matter most for each molecule class. This allows us to achieve high purity with significantly fewer operational steps.
Industrial scale up
Askleia technologies are designed with industrial transferability as a core constraint. Every process decision is evaluated not only for scientific performance but for practical implementability — equipment compatibility, regulatory readiness, raw material availability, and cost at volume.
Competitive Differentiation
Askleia vs Conventional Chromatography
| Criteria | Conventional | ASKLEIA |
|---|---|---|
| Ligand cost | High (Protein A) | Reduced |
| Resin cost | High | No resin |
| Number of steps | 3–5 | 1–2 |
| Buffer consumption | High | Significantly reduced |
| Scale-up complexity | Not applicable | ✓ |
| Process flexibility | Not applicable | ✓ |
| Mode of operation | Batch or semi-batch | Continuous-compatible |
| Scale of equipment | Large | Compact |
| Resin fouling | Frequent | Not applicable |
| Resin regeneration | Frequent | Not applicable |
| Footprint | Large | Limited |
Contact :
Hours: 9 a.m. – 5 p.m., Monday to Friday
Phone: +33 4 42 01 90 59
Address: 510 Avenue de Jouques, Pôle Performance, Building C2, 13400 Aubagne
